ROSWELL, Ga. Â- Kimberly-Clark Health Care announced today that it will be shifting the production of exam gloves from latex to synthetic alternatives over the next four to 18 months. The company made this business decision in support of the growing customer demand for synthetic solutions such as its latest glove offering, STERLING* Nitrile, and its market-leading PURPLE NITRILE* Exam Gloves, and in response to unprecedented increases in the cost of latex raw materials.
Since 2002, virtually every aspect of the exam glove manufacturing supply chain has incurred significant cost increases. The latex category has been especially affected with raw materials costs increasing over 300 percent since 2002. In addition, energy costs have increased 274 percent during that same period.Â
Kimberly-Clark Health Care President Joanne Bauer says that cost and supply issues combined with increased demand for protective products related to pandemic preparedness efforts are creating a radical change in the dynamics of the glove business, forcing manufacturers to reconsider production and supply strategies.
Over time, increased costs in latex raw materials will be passed along to our customers; we do not see any macroeconomic trends to suggest otherwise, Bauer says. As this happens, high-quality, synthetic alternatives to latex, which do not sacrifice worker and patient safety, will continue to become more affordable, removing cost as the last significant barrier to changing to a latex-free system. We are committed to delivering on our brand promise of eliminating caregivers worries about using products that could potentially compromise their health or put their patients at risk of adverse outcomes.
In January 2006, the company officially introduced STERLING* Nitrile, its latest synthetic examination glove innovation, as the ideal alternative for facility-wide conversion away from latex gloves. The healthcare community recognizes the profound implications of latex, and we have worked diligently to develop a synthetic glove that combines the dexterity and sensitivity of latex with the strength and superior barrier protection qualities of nitrile, said John Amat, vice president of sales and marketing, Kimberly-Clark Health Care. Through a combination of proprietary materials and manufacturing processes, we have been able to develop this superior glove and offer it at a great overall value.
Amat said that the availability of a better alternative to latex in terms of both comfort and pricing helps to make a compelling case for facilities to use latex-free solutions. We continually look for alternate materials that are, in general, safer for use by caregivers and can help facilities mitigate the effects of rising raw materials, energy and transportation costs that are all reflected in manufacturers pricing, Â said Amat. Kimberly-Clark is known for superior quality, not for being the lowest-priced provider, and were not going to compromise that or our brand. Through innovations like STERLING* Nitrile Exam Gloves, we can pass along to our customers efficiencies in our manufacturing processes and finally offer a solution to the marketplace that leaves little room for debating the benefits of being latex-free.
Source: Kimberly-Clark
Â
Â
Â
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
COVID-19 Realities: Beyond a Respiratory Virus, Addressing Optimism in Pandemic Management
February 28th 2024A recent commentary by Dr. Amesh Adalja in MedPage Today challenges the perception of COVID-19 as solely a respiratory virus, highlighting its broader impact on the body. This analysis questions the notion that COVID-19 should be managed like common respiratory infections, urging a closer look at vaccine effectiveness, the rise of long COVID, and the need for enhanced measures to curb the virus's spread. Let's explore the complexities of COVID-19 management and the pressing realities faced by the US and the world.
The Neglected Tropical Diseases You’ve Never Heard Of
February 27th 2024The 20 conditions, known as neglected tropical diseases (NTDs), are estimated to affect more than 1 billion people, yet many individuals have never heard of them. Heather Saunders, MPH, RN, CIC, discusses 5 of them and what is being done to prevent their spread.